GSK Expects Upper End of Growth Targets Following Q2 Results

GSK reports Q2 revenue of £8bn, up 6% at constant exchange rates, driven by strong sales of specialty medicines. The company now expects annual revenue growth at the upper end of 3-5%, and growth in operating profit and core earnings per share at the upper end of 6-8%. Core operating profit rose 12% to £2.6bn, while EPS increased 15% to 46.5 pence.

GSK plc (GSK) reported its second-quarter earnings for the period ending June 30, 2025, with a notable increase in revenue and profit driven primarily by the robust performance of its specialty medicines business. The London-based pharmaceutical giant announced a revenue of £8 billion, up 6% at constant exchange rates compared to the same period last year. This figure exceeded analysts' expectations of £7.8 billion [3].

The company's net profit rose to £1.44 billion from £1.17 billion in the second quarter of 2024. Core operating profit, a key metric for investors, increased by 12% to £2.63 billion, up from £2.51 billion. This growth was largely attributed to the strong performance of specialty medicines, which contributed significantly to the overall financial results [3].

GSK's earnings per share (EPS) also showed a significant improvement, increasing by 15% to 46.5 pence. This figure surpassed the average estimate of five analysts surveyed by Zacks Investment Research, which was for earnings of 39.8 pence per share [1].

The company declared a dividend of 16 pence per share for the second quarter and expects to pay out a total of 64 pence for the full year. GSK has a history of beating earnings estimates, having done so 100% of the time over the last two years [2].

Looking ahead, GSK is optimistic about its full-year prospects. The company expects annual revenue growth to be at the upper end of its previously provided range of 3% to 5%. Additionally, it anticipates growth in core operating profit toward the upper end of its range of between 6% and 8% [3].

References:
[1] https://finance.yahoo.com/news/glaxo-q2-earnings-snapshot-090346408.html
[2] https://seekingalpha.com/news/4473401-gsk-q2-2025-earnings-preview
[3] https://www.tradingview.com/news/DJN_DN20250730002307:0-gsk-upbeat-on-guidance-after-specialty-medicines-boost-sales/